Eurofins to Expand Drug Discovery Capabilities Through Beacon Discovery Acquisition

BioPharm International Editors

With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.

Eurofins Scientific announced on Feb. 18, 2021 that it is acquiring Beacon Discovery, a US-based drug discovery and contract research organization, to expand its drug discovery capabilities.

According to a Eurofins press release, the company decided to acquire Beacon because of its experience in drug discovery and development, along with its knowledge of G-protein coupled receptor (GPCR) research and its compound library.

“Beacon Discovery is very excited to join Eurofins,” said Dr. Sunny Al-Shamma, Beacon Discovery’s CEO, in the press release. “Joining the Eurofins Discovery organization expands our opportunity to continue our drug discovery efforts and provide integrated drug discovery services with the additive and complementary capabilities provided by Eurofins Discovery.”

“Beacon Discovery adds the expertise in GPCR targets and drug discovery and development experience that will advance our offering in integrated drug discovery services for our clients,” said Dr. Gilles Martin, Eurofins’ CEO, in the press release. “This transaction is another demonstration of Eurofins’ commitment to provide the most comprehensive portfolio of laboratory services in the discovery pharmacology field which enjoys a strong outsourcing growth trend.”

Source: Eurofins